SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 ...
SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies SOMERVILLE, Mass., Dec. 1, 2025 ...
Generate:Biomedicines (Generate), a technology company founded at the intersection of machine learning, biological engineering, and medicine, announced it plans to initiate two global phase 3 clinical ...
The treatment uses a modified, harmless virus to deliver healthy genes to a patient’s cells to treat genetic diseases. Read ...
AC Immune receives a "Buy" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's ...
From reference-grade loudspeakers and AV processors to subwoofers and headphones, 2025 delivered standout audio and home ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback